




RealRate

PHARMACEUTICAL 2017

Cara Therapeutics Inc.
Rank 240 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

Cara Therapeutics Inc.
Rank 240 of 313



The relative strengths and weaknesses of Cara Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cara Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 167% points. The greatest weakness of Cara Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 323% points.

The company's Economic Capital Ratio, given in the ranking table, is -464%, being 48% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	61,445
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,533
Liabilities, Non-Current	0
Other Assets	769
Other Compr. Net Income	38
Other Expenses	-468
Other Liabilities	0
Other Net Income	652
Property and Equipment	1,614
Research and Development	49,253
Revenues	86
Selling, General and Administrative Expense	9,233

Output Variable	Value in 1000 USD
Assets	63,828
Liabilities	11,533
Expenses	58,018
Stockholders Equity	52,295
Net Income	-57,280
Comprehensive Net Income	-57,261
Economic Capital Ratio	-464%

